CANY
BHVN

Caxton Associates (New York)’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Caxton Associates (New York)’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,621
Closed -$289K – 586
2019
Q1 		$289K Buy
+5,621
New +$243K 0.04% 263

Other funds holding BHVN

Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Caxton Associates (New York)'s BHVN Position: Q2 2019 in Review

Caxton Associates (New York) sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2019, closing a stake of 5,621 shares — an estimated $289K sold.

Caxton Associates (New York) first reported a position in BHVN in Q1 2019 and held it in 1 quarter. The position peaked at $289K in Q1 2019. 197 funds tracked by Wall St. Rank hold BHVN as of Q2 2019.

  • Caxton Associates (New York) reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2019 after selling out during the quarter.
  • Caxton Associates (New York) sold 5,621 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2019, an estimated $289K.
  • Caxton Associates (New York) first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 1 quarter.
  • Caxton Associates (New York)'s Biohaven Pharmaceutical Holding Company Ltd. position peaked at $289K in Q1 2019.
  • 197 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2019.

Based on Caxton Associates (New York)'s 13F filing for Q2 2019, filed 14 Aug 2019.